Bessemer Group Inc. Raises Holdings in Eli Lilly and Company (LLY)

Bessemer Group Inc. grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,177,106 shares of the company’s stock after acquiring an additional 1,247 shares during the period. Eli Lilly and accounts for 1.1% of Bessemer Group Inc.’s holdings, making the stock its 14th largest position. Bessemer Group Inc. owned about 0.29% of Eli Lilly and worth $271,770,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. Swiss National Bank lifted its position in Eli Lilly and by 0.9% during the third quarter. Swiss National Bank now owns 4,157,443 shares of the company’s stock worth $355,628,000 after acquiring an additional 36,000 shares during the last quarter. Jaffetilchin Investment Partners LLC raised its position in shares of Eli Lilly and by 119.6% in the third quarter. Jaffetilchin Investment Partners LLC now owns 10,628 shares of the company’s stock valued at $909,000 after buying an additional 5,789 shares in the last quarter. Maple Capital Management Inc. raised its position in shares of Eli Lilly and by 2.4% in the third quarter. Maple Capital Management Inc. now owns 96,166 shares of the company’s stock valued at $8,226,000 after buying an additional 2,270 shares in the last quarter. Jacobi Capital Management LLC raised its position in shares of Eli Lilly and by 65.7% in the third quarter. Jacobi Capital Management LLC now owns 1,718 shares of the company’s stock valued at $150,000 after buying an additional 681 shares in the last quarter. Finally, Blackhill Capital Inc. raised its position in shares of Eli Lilly and by 0.6% in the third quarter. Blackhill Capital Inc. now owns 154,915 shares of the company’s stock valued at $13,251,000 after buying an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 76.42% of the company’s stock.

LLY has been the subject of a number of analyst reports. Jefferies Group reiterated a “buy” rating and issued a $89.00 price target on shares of Eli Lilly and in a research report on Monday, September 11th. BMO Capital Markets reiterated an “underperform” rating and issued a $71.00 price target (down from $73.00) on shares of Eli Lilly and in a research report on Wednesday, September 6th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their price target for the company from $84.23 to $88.00 in a research report on Tuesday, October 10th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $105.00 price target (up from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Finally, Berenberg Bank reiterated a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a research report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $90.25.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of Eli Lilly and stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total value of $17,796,050.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Jeffrey N. Simmons sold 12,500 shares of Eli Lilly and stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the completion of the transaction, the senior vice president now directly owns 124,522 shares in the company, valued at $10,766,172.12. The disclosure for this sale can be found here. Insiders sold 651,088 shares of company stock worth $56,439,586 over the last three months. 0.20% of the stock is currently owned by insiders.

Eli Lilly and Company (NYSE:LLY) opened at $86.54 on Friday. The stock has a market cap of $95,244.73, a P/E ratio of 21.15, a P/E/G ratio of 1.76 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Company has a one year low of $71.76 and a one year high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The business had revenue of $5.66 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the firm posted $0.88 earnings per share. equities analysts anticipate that Eli Lilly and Company will post 4.22 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.60%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.

COPYRIGHT VIOLATION WARNING: “Bessemer Group Inc. Raises Holdings in Eli Lilly and Company (LLY)” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://sportsperspectives.com/2017/12/16/bessemer-group-inc-raises-holdings-in-eli-lilly-and-company-lly.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply